论文部分内容阅读
目的:探讨醒脑静联合尤瑞克林治疗急性脑梗塞患者临床疗效及其安全性评价,为临床诊断治疗提供科学依据。方法:102例患者随机分为对照组和观察组,对照组注射用尤瑞克林针,观察组在对照组基础上结合醒脑静治疗。结果:观察组治疗后总有效率和神经功能缺损评分显著高于对照组,且差异具有统计学意义(P<0.05);观察组治疗后MDA水平显著低于治疗前及同期对照组,且差异具有统计学意义(P<0.05);观察组治疗后SOD水平显著高于治疗前及同期对照组,且差异具有统计学意义(P<0.05);观察组治疗后血浆黏度、全血黏度及红细胞聚集指数显著低于治疗前,且差异具有统计学意义(P<0.05);两组不良反应发生率比较无统计学差异(P>0.05)。结论:醒脑静联合尤瑞克林治疗急性脑梗塞疗效显著,且无明显不良反应,值得临床应用推广。
Objective: To investigate the clinical efficacy and safety evaluation of Xingnaojing combined with Urelin in the treatment of acute cerebral infarction, and provide a scientific basis for clinical diagnosis and treatment. Methods: 102 patients were randomly divided into control group and observation group. The control group received uracil needle injection. The observation group was treated with xingnaojing on the basis of the control group. Results: The total effective rate and neurological deficit score of the observation group after treatment were significantly higher than those of the control group (P <0.05). The MDA level of the observation group was significantly lower than that of the control group before and after treatment (P <0.05). The level of SOD in the observation group was significantly higher than that in the control group before and after treatment (P <0.05), and the plasma viscosity, whole blood viscosity and red blood cells Aggregation index was significantly lower than before treatment, and the difference was statistically significant (P <0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P> 0.05). Conclusion: The combination of xingnaojing and uracil is effective in treating acute cerebral infarction with no obvious adverse reactions, which is worthy of clinical application.